Idiopathic pulmonary fibrosis trials in United States

In United States 44 Also abroad 111

44 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Where
Albuquerque, Ann Arbor, Atlanta, Aurora, Austin, Birmingham, Boston, Buffalo, Chapel Hill, Charlottesville, Chicago, Cleveland, Columbus, Draper, Honolulu, Kansas City, Knoxville, Madison, New York, Novi, Omaha, Philadelphia, Rockville, San Diego, Santa Rosa, Seattle, Shreveport, Tampa, Towson, Tucson, Worcester
Age
18 years to 80 years
People
100
Run by
Reunion Neuroscience Inc
See details and how to joinNCT07002034
Phase 2Not yet taking people in United States
A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment
Where
Boston, Charleston, Cleveland, Dallas, DuBois, Durham, New Haven, Pensacola, Rochester, Salt Lake City, Tucson
Age
40 years and over
People
70 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07926321 · EU 2026-527098-13-00
Phase 2Taking people
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
Where
Atlanta, Aurora, Baltimore, Bend, Birmingham, Charleston, Cincinnati, El Paso, Falls Church, Farmington, Hannibal, Houston, Kansas City, Los Angeles, Murray, Nashville, New Haven, Newport Beach, New York, Ocala, Philadelphia, Portland, Rochester, Salt Lake City, Seattle, Statesville, Winston-Salem
Age
18 years and over
People
340 worldwide
Run by
Avalyn Pharma Inc.
See details and how to joinNCT06951217
Phase 2Taking people
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Where
Birmingham, Chapel Hill, Charleston, Chesterfield, Cincinnati, Denver, Detroit, El Paso, Houston, Indianapolis, Kansas City, Los Angeles, New Haven, New York, Salt Lake City, San Diego, Temple, Weston, Winston-Salem
Age
40 years and over
People
120 worldwide
Run by
Rein Therapeutics
See details and how to joinNCT06968845 · EU 2025-520715-13-00
Phase 3Taking people
A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)
Where
DuBois
Age
18 years to 85 years
People
800
Run by
Insmed Incorporated
See details and how to joinNCT07805785 · EU 2026-525924-37-00
Phase 3Not yet taking people in United States
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Where
Birmingham, Ocala, Philadelphia
Age
18 years and over
People
2,380 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07441408 · EU 2025-522373-10-00
Phase 2Taking people
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
Where
Ann Arbor, Atlanta, Aurora, Baltimore, Birmingham, Boise, Boston, Burlington, Champaign, Charleston, Chicago, Cincinnati, Dallas, Denver, Detroit, El Paso, Fountain Hill, Greensboro, Houston, Kansas City, Lexington, Loma Linda, Los Angeles, Newport Beach, New York, Ocala, Oklahoma City, Philadelphia, Phoenix, Richmond, Sacramento, Stanford, Weston
Age
40 years and over
People
359 worldwide
Run by
AstraZeneca
See details and how to joinNCT07652658
No phaseTaking people
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
Where
New York
Age
18 years and over
People
2,000
Run by
Weill Medical College of Cornell University
See details and how to joinNCT01776398
Phase 3Taking people
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Where
Cypress, Denison, DuBois, El Paso, Franklin, Greensboro, Hialeah, Kissimmee, Knoxville, North Dartmouth, Palm Spring, Redding, Reno, Rock Hill, The Woodlands, Webster
Age
40 years and over
People
1,100 worldwide
Run by
PureTech
See details and how to joinNCT07284602 · EU 2025-524493-42-00
Phase 2Not yet taking people in United States
Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis
Where
Birmingham, Chapel Hill, Chicago, Kansas City, Philadelphia, Pittsburgh, Salt Lake City
Age
40 years to 85 years
People
52
Run by
University of Alabama at Birmingham
See details and how to joinNCT07674745
Phase 3Enrolling by invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Where
Albuquerque, Ann Arbor, Atlanta, Baltimore, Birmingham, Boston, Charleston, Charlottesville, Chesterfield, Chicago, Cincinnati, Cleveland, Columbia, Columbus, Commack, Dallas, Denver, Durham, Falls Church, Franklin, Gainesville, Greensboro, Greenville, Hershey, Houston, Jackson, Jacksonville, Kansas City, Kissimmee, Knoxville, La Jolla, Los Angeles, Louisville, Madison, Maywood, McAllen, McKinney, Milwaukee, Minneapolis, Murray, Nashville, New Hyde Park, New Orleans, Newport Beach, New York, Oklahoma City, Omaha, Orlando, Philadelphia, Phoenix, Portland, Richmond, Rochester, Rock Hill, Royal Oak, Sacramento, Salt Lake City, San Francisco, Shreveport, Silver Spring, Stanford, St Louis, Tampa, The Bronx, The Woodlands, Tucson, Weston, Winston-Salem
Age
40 years and over
People
1,850 worldwide
Run by
United Therapeutics
See details and how to joinNCT04905693
Phase 2Taking people
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
Where
Denison, Dothan, Hannibal, Hendersonville, Rock Hill, St. Petersburg
Age
40 years and over
People
240 worldwide
Run by
Chiesi Farmaceutici S.p.A.
See details and how to joinNCT07516951 · EU 2024-514246-37-00
Phase 2Taking people
Study of ORJ-001 for the Treatment of IPF
Where
Doral, DuBois
Age
40 years and over
People
95
Run by
Oorja Bio, Inc.
See details and how to joinNCT07869147
Phase 3Taking people
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
Where
Anderson, Brandon, Cypress, DuBois, El Paso, Gastonia, Hannibal, Houston, Kissimmee, Lakewood, Loxahatchee Groves, Miami, Murray, New Orleans, Newport Beach, Palm Springs, Redding, Reno, Richmond, St. Petersburg, The Bronx, Winston-Salem
Age
40 years and over
People
306
Run by
Trevi Therapeutics
See details and how to joinNCT07671911 · EU 2026-525877-38-00
No phaseTaking people
Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring
Where
San Francisco
Age
18 years and over
People
200
Run by
University of California, San Francisco
See details and how to joinNCT07673237
Phase 3Taking people
Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets
Where
Charlotte, North Miami Beach, Sugar Land, Wilmington
Age
40 years and over
People
201
Run by
Trevi Therapeutics
See details and how to joinNCT07868419
No phaseTaking people
Pulmonary Fibrosis Foundation Community Registry
Where
Chicago
Age
18 years and over
People
10,000
Run by
Pulmonary Fibrosis Foundation
See details and how to joinNCT05382572
No phaseTaking people
SUPPORT-T in Patients With Progressive Pulmonary Fibrosis and Their Caregivers
Where
Charleston
Age
18 years and over
People
170
Run by
Medical University of South Carolina
See details and how to joinNCT07269262
Phase 3Not yet taking people in United States
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
Where
Ann Arbor, Aurora, Boston, Chicago, Dallas, Houston, New York, Philadelphia, Rochester, Salt Lake City, Seattle, Tucson, Washington D.C., Worcester
Age
40 years and over
People
800
Run by
University of Massachusetts, Worcester
See details and how to joinNCT07520110
Phase 2Taking people
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
Where
Ann Arbor, Birmingham, Champaign, Detroit, Dothan, Falls Church, Hannibal, Kissimmee, Philadelphia, Richmond
Age
40 years and over
People
165 worldwide
Run by
AbbVie
See details and how to joinNCT07230288 · EU 2024-518013-25-00
Phase 2Taking people
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Where
Bend, Chapel Hill, Chicago, Dallas, Denison, Dickson, Farmington, Indianapolis, Jacksonville, Kansas City, La Mesa, Louisville, Madison, Miami, New York, Philadelphia, Rochester, Royal Oak, San Francisco, Sioux Falls
Age
40 years and over
People
128
Run by
Cumberland Pharmaceuticals
See details and how to joinNCT05571059
No phaseTaking people
Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)
Where
Pittsburgh
Age
18 years and over
People
2,000
Run by
University of Pittsburgh
See details and how to joinNCT00258570
No phaseTaking people
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
Where
Pittsburgh
Age
18 years and over
People
500
Run by
University of Pittsburgh
See details and how to joinNCT00373841
No phaseTaking people
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
Where
Ann Arbor, Aurora, Charlottesville, Dallas, New York, Seattle, Worcester
Age
18 years to 80 years
People
500 worldwide
Run by
University of Massachusetts, Worcester
See details and how to joinNCT06855329
No phaseTaking people
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Where
Ann Arbor, Atlanta, Aurora, Austell, Birmingham, Chapel Hill, Charleston, Charlottesville, Chicago, Cincinnati, Cleveland, Colchester, Columbus, Dallas, Detroit, Durham, Evanston, Falls Church, Gainesville, Greensboro, Houston, Jackson, Kansas City, Los Angeles, Maywood, Milwaukee, Minneapolis, Nashville, New Haven, New Orleans, New York, Oklahoma City, Philadelphia, Portland, Salt Lake City, Stanford, St Louis, Tampa, Tucson, Wilmington, Winston-Salem
Age
21 years and over
People
3,000
Run by
Duke University
See details and how to joinNCT01915511